Recently, in a phase Ib/IIa clinical trial, MIS416 was shown to suppress the development of proinflammatory T helper, and to increase the serum levels of IFN-γ and IFN-γ-associated proteins in 19 patients with SPMS [83]. This evidence concerns the gene IFNG and secondary progressive multiple sclerosis.